What is the optimal initiation timing of angiotensin converting enzyme inhibitor treatment for maximum benefits in acute myocardial infarction patients?

被引:0
|
作者
Yan Hong-bing [1 ,2 ,3 ]
Wang Shao-ping [4 ]
机构
[1] Chinese Acad Med Sci, Coronary Heart Dis Ctr, Cardiovasc Inst, Beijing 100037, Peoples R China
[2] Chinese Acad Med Sci, Fu Wai Hosp, Beijing 100037, Peoples R China
[3] Peking Union Med Coll, Beijing 100037, Peoples R China
[4] Capital Med Univ, Div 28, Beijing Anzhen Hosp, Beijing 100029, Peoples R China
关键词
angiotensin-converting enzyme inhibitor; acute myocardial infarction; left ventricular remodeling; LEFT-VENTRICULAR DYSFUNCTION; INTRACORONARY ENALAPRILAT; THROMBOLYSIS; CAPTOPRIL; MORTALITY; FOSINOPRIL; MORBIDITY; SURVIVAL;
D O I
10.3760/cma.j.issn.0366-6999.2011.03.026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Randomized clinical trials led to the clinical recommendation that angiotensin-converting enzyme inhibitors (ACEI) should be used as standard therapy in most patients experiencing an acute myocardial infarction (AMI). However, the optimal initiation timing of treatment, as well as the exact mechanisms, have not been completely resolved, especially with the development of reperfusion strategy after AMI. Earlier initiation of ACEI might be associated with more prompt recovery of left ventricular ejection fraction due to more rapid attenuation of negative remodeling. Chin Med J 2011;124(3):464-466
引用
收藏
页码:464 / 466
页数:3
相关论文
共 50 条
  • [1] Angiotensin converting enzyme in patients with acute myocardial infarction - a paradigm shift
    Grajek, Stefan
    KARDIOLOGIA POLSKA, 2016, 74 : 13 - 18
  • [2] Relationship Between Beta-Blocker and Angiotensin-Converting Enzyme Inhibitor Dose and Clinical Outcome Following Acute Myocardial Infarction
    Grall, Sylvain
    Biere, Loic
    Le Nezet, Marie
    Bouvier, Jean-Marc
    Lucas-Chauvelon, Pierre
    Richard, Claude
    Abi-Khalil, Wissam
    Delepine, Stephane
    Prunier, Fabrice
    Furber, Alain
    CIRCULATION JOURNAL, 2015, 79 (03) : 632 - +
  • [3] Effects of Valsartan, an Angiotensin II Receptor Blocker, on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction Who Receive an Angiotensin-Converting Enzyme Inhibitor
    Yano, Hideto
    Hibi, Kiyoshi
    Nozawa, Naoki
    Ozaki, Hiroyuki
    Kusama, Ikuyoshi
    Ebina, Toshiaki
    Kosuge, Masami
    Tsukahara, Kengo
    Okuda, Jun
    Morita, Satoshi
    Umemura, Satoshi
    Kimura, Kazuo
    CIRCULATION JOURNAL, 2012, 76 (06) : 1442 - 1451
  • [4] Comparison of 5-Year Survival After Acute Myocardial Infarction Using Angiotensin-Converting Enzyme Inhibitor Versus Angiotensin II Receptor Blocker
    Hara, Masahiko
    Sakata, Yasuhiko
    Nakatani, Daisaku
    Suna, Shinichiro
    Usami, Masaya
    Matsumoto, Sen
    Sugitani, Toshifumi
    Nishino, Masami
    Sato, Hiroshi
    Kitamura, Tetsuhisa
    Nanto, Shinsuke
    Hamasaki, Toshimitsu
    Hori, Masatsugu
    Komuro, Issei
    AMERICAN JOURNAL OF CARDIOLOGY, 2014, 114 (01) : 1 - 8
  • [5] Effects of Enalapril and Losartan in Left Ventricular Remodeling after Acute Myocardial Infarction: A Possible Mechanism of Prevention of Cardiac Events by Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in High-risk Myocardial Infarction
    Tani, Shigemasa
    Nagao, Ken
    Anazawa, Takeo
    Kawamata, Hirofumi
    Furuya, Shingo
    Takahashi, Hiroshi
    Iida, Kiyoshi
    Matsumoto, Michiaki
    Kumabe, Narimichi
    Onikura, Motoyuki
    Hirayama, Atsushi
    INTERNAL MEDICINE, 2009, 48 (11) : 877 - 882
  • [6] The Use of Angiotensin Converting Enzyme Inhibitors in Patients After Myocardial Infarction
    Preobrazhensky, D. V.
    Sidorenkid, B. A.
    Batyraliev, T. A.
    Fettser, D. V.
    Islek, M.
    KARDIOLOGIYA, 2008, 48 (11) : 64 - 68
  • [7] Distinct Survival Benefits of Angiotensin-Converting Enzyme Inhibitors/Angiotensin II Receptor Blockers in Revascularized Coronary Artery Disease Patients According to History of Myocardial Infarction
    Nishino, Tomohiro
    Furukawa, Yutaka
    Kaji, Shuichiro
    Ehara, Natsuhiko
    Shiomi, Hiroki
    Kim, Kitae
    Kitai, Takeshi
    Kinoshita, Makoto
    Morimoto, Takeshi
    Sakata, Ryuzo
    Kimura, Takeshi
    CIRCULATION JOURNAL, 2013, 77 (05) : 1242 - 1252
  • [8] Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors in Acute Myocardial Infarction Without Heart Failure
    Kim, Jihoon
    Kang, Danbee
    Park, Hyejeong
    Park, Taek Kyu
    Lee, Joo Myung
    Yang, Jeong Hoon
    Song, Young Bin
    Choi, Jin-Ho
    Choi, Seung-Hyuk
    Gwon, Hyeon-Cheol
    Guallar, Eliseo
    Cho, Juhee
    Hahn, Joo-Yong
    AMERICAN JOURNAL OF MEDICINE, 2024, 137 (11) : 1088 - 1096.e4
  • [9] Effect of angiotensin converting enzyme inhibitors on periprocedural myocardial infarction in patients with metabolic syndrome
    Ozcan, Ozgur Ulas
    Ustun, Elif Ezgi
    Gulec, Sadi
    Gerede, Demet Menekse
    Goksuluk, Huseyin
    Vurgun, Veysel Kutay
    Kaya, Cansin Tulunay
    Erol, Cetin
    CARDIOLOGY JOURNAL, 2015, 22 (03) : 323 - 329
  • [10] Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
    Lim, Sungmin
    Choo, Eun Ho
    Choi, Ik Jun
    Ihm, Sang-Hyun
    Kim, Hee-Yeol
    Ahn, Youngkeun
    Chang, Kiyuk
    Jeong, Myung Ho
    Seung, Ki-Bae
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2019, 34 (45)